22.56
-1.36%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jiangsu Nhwa Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002262.SZ. It has been listed since 23 July 2008. In the fiscal year to 31 December 2025, it reported revenue of CN¥5.91bn and net income of CN¥1.06bn. At that date it held total assets of CN¥9.22bn and shareholders' equity of CN¥8.06bn.
Jiangsu Nhwa Pharmaceutical Co., Ltd. engages in the pharmaceutical production, research and development, and sales. The company is headquartered in Xuzhou, Jiangsu. The company went IPO on 2008-07-23. The firm offers its pharmaceutical products under four categories, which consist of anesthetic medicines, including midazolam injections and etomidate fat emulsion pharmaceutical preparations injections; psychiatric medicines, including risperidone tablets and others; neurological medicines, including gabapentin capsules and others; bulk drugs, including fenofibrate and miconazole nitrate. The firm is also engaged in the pharmaceuticals trading business. Through its subsidiaries, the Company is also engaged in the Internet medical businesses. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 Jul 2008
- Employees
- 4,955
- Website
- nhwa-group.com ↗
Leadership
Pay as last reported
- Mr. Pengsheng SunChairman of the Board, since 2007CN¥250,000
- Mr. Gangsheng LiChief Financial OfficerCN¥633,600
- Mr. Jiaquan SunGeneral Manager, Director, since 2009CN¥4.8m
- Mr. Baozhou DuanDeputy General Manager, Secretary of the BoardCN¥413,700
- Mr. Zengliang ChenDeputy General Manager, Director, since 2007CN¥200,000
- Mr. Qing FuDeputy General Manager, Director, since 2007CN¥200,000
- Mr. Ziliang YangDeputy General Manager, Director, since 2007CN¥200,000
- Mr. Guoxiang ChenIndependent DirectorCN¥50,000
- Ms. Yulan LiIndependent DirectorCN¥50,000
- Mr. Xiaoxing YinIndependent DirectorCN¥50,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 30
- Environment
- 17
- Social
- 23
- Governance
- 51
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company employs 4955 full-time employees
- Offers pharmaceutical products in four categories including anesthetic, psychiatric, neurological, and bulk drugs
- Engaged in pharmaceutical production, R&D, and sales
Weaknesses
- No specific weaknesses mentioned in the provided information
- No details on financial performance or market share provided
- No information on competitive advantages or unique technologies
Opportunities
- Expanding into Internet medical businesses through subsidiaries
- Distributing products domestically and to overseas markets
- Engaged in pharmaceutical trading business
Threats
- No specific threats mentioned in the provided information
- No details on regulatory challenges or market competition
- No information on potential risks in the pharmaceutical industry
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.